+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Multiple Myeloma Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 293 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 992789

Global Multiple Myeloma Therapeutics Market to Reach $66.9 Billion by 2030

The global market for Multiple Myeloma Therapeutics estimated at US$22.2 Billion in the year 2022, is projected to reach a revised size of US$66.9 Billion by 2030, growing at a CAGR of 14.8% over the analysis period 2022-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is projected to record a 15.5% CAGR and reach US$37.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Radiation segment is readjusted to a revised 14.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $6 Billion, While China is Forecast to Grow at 20% CAGR

The Multiple Myeloma Therapeutics market in the U.S. is estimated at US$6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$16 Billion by the year 2030 trailing a CAGR of 20% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.8% and 12.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$10.3 Billion by the year 2030.

Select Competitors (Total 49 Featured) -

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International AG
  • Sanofi Genzyme

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Multiple Myeloma Therapeutics

What is the estimated value of the Global Market for Multiple Myeloma Therapeutics?

The Global Market for Multiple Myeloma Therapeutics was estimated to be valued at $22.2 Billion in 2022.

What is the growth rate of the Global Market for Multiple Myeloma Therapeutics?

The growth rate of the Global Market for Multiple Myeloma Therapeutics is 14.8%, with an estimated value of $66.9 Billion by 2030.

What is the forecasted size of the Global Market for Multiple Myeloma Therapeutics?

The Global Market for Multiple Myeloma Therapeutics is estimated to be worth $66.9 Billion by 2030.

Who are the key companies in the Global Market for Multiple Myeloma Therapeutics?

Key companies in the Global Market for Multiple Myeloma Therapeutics include Amgen, Inc., Bristol, Myers Squibb Company, Bristol, Myers Squibb Company, Celgene Corporation, Janssen Biotech, Inc., Juno Therapeutics, Inc., Kesios Therapeutics Ltd. and Novartis International AG.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Multiple Myeloma Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Multiple Myeloma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Chemotherapy & Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Chemotherapy & Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Chemotherapy & Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Radiation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Stem Cell Transplant & Supportive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Stem Cell Transplant & Supportive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Stem Cell Transplant & Supportive Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Multiple Myeloma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 15: USA Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: USA 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: Canada 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
JAPAN
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: Japan 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
CHINA
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: China Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: China 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
EUROPE
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Multiple Myeloma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Europe 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
FRANCE
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: France Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: France 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
GERMANY
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Germany 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Italy 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: UK Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: UK 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
SPAIN
  • Table 44: Spain Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Spain Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Spain 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
RUSSIA
  • Table 47: Russia Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Russia Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Russia 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 50: Rest of Europe Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Rest of Europe Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Rest of Europe 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for Multiple Myeloma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Multiple Myeloma Therapeutics by Type - Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Multiple Myeloma Therapeutics by Type - Percentage Breakdown of Value Sales for Chemotherapy & Other Drugs, Radiation and Stem Cell Transplant & Supportive Treatment for the Years 2014, 2023 & 2030
AUSTRALIA
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Multiple Myeloma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Executive Summary

Multiple Myeloma, a lethal but less common type of blood cancer results in eventual patient relapses even after therapy, and is universally considered as fatal. More than 181,000 individuals suffered from the condition across major regions worldwide, including the US, EU, and Japan in the year 2010, with an estimated 52,000 new cases diagnosed during the year. The condition primarily affects the aged, given the average age of disease onset at around 70 years. Stem cell therapy has been available for treating the condition for several years, and novel drugs that forayed into the market over the years have largely been effective. However, the stem cell transplantation has been more fruitful in younger patient population, and high unmet needs existed for long in high-risk patients. The subsequent launch of new drug agents, such as thalomide, bortezomib, and lenalidomide have succeeded in making a substantial impact on the treatment outcomes in patients of all age groups.

The US represents the largest regional market for multiple myeloma therapeutics worldwide, as stated by the new market research report on Multiple Myeloma Therapeutics. Europe remains the second largest market for multiple myleoma therapeutics worldwide. However, Rest of World, which includes markets such as Canada, Asia-Pacific, Latin America, Africa, and the Middle East, is forecast to garner the fastest growth during the analysis period. Japanese market is projected to tread at a compounded annual growth rate of close to 10% during the analysis period.

Revlimid’s approval for use as a drug in the first line treatment of multiple myeloma has sparked a new momentum for the sales of this drug. Consequently, Revlimid is expected to cannibalize significant share of Velcade in the myeloma therapy market in value terms as well as in terms of the drug’s share in number of patients using the drug. However, the cannibalizing effect is expected to be more profound in case of Thalomid when compared to Velcade. Despite this threat, sales of Velcade and Revlimid are expected to increase, specifically in the patient segment with relapsed/refractory forms of myeloma.

Major players profiled in the report include Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech Inc., Janssen Biotech Inc, Millennium Pharmaceuticals, Seattle Genetics, Ziopharm Oncology Inc., among others.

The research report titled “Multiple Myeloma Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the multiple myeloma therapeutics markets, current market trends, key growth drivers, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Multiple Myeloma Therapeutics market for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

Global Industry Analysts ©

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International AG
  • Sanofi Genzyme